Brand Intelligence Graphcompany
Company Overview
About Agilent Technologies
Agilent Technologies, Inc. is a Santa Clara, California-based life sciences, diagnostics, and applied chemical analysis instruments company — publicly traded on the New York Stock Exchange (NYSE: A) as an S&P 500 Health Care component — designing, manufacturing, and supporting analytical instruments, consumables, software, and services for pharmaceutical, biopharmaceutical, food safety, environmental, clinical, and academic laboratory applications through approximately 17,000 employees worldwide. In fiscal year 2025 (ending October 2025), Agilent reported full-year revenue of $6.95 billion, with Q4 FY2025 revenue of $1.86 billion (+9.4% reported, +7.2% core growth) — accelerating from the prior year's market correction when the pharmaceutical and biopharma industry destocked lab consumables following the COVID-era inventory surge. The Life Sciences and Diagnostics Markets Group delivered Q4 FY2025 revenue of $755 million (+15% reported, +11% core), reflecting a robust recovery in pharmaceutical R&D laboratory spending. Founded in 1999 as a spinoff from Hewlett-Packard's analytical instruments division (carrying forward HP's tradition of precision measurement instruments dating to 1939), Agilent is organized around three segments: Life Sciences & Applied Markets (liquid chromatography, mass spectrometry, gas chromatography systems for drug development and food/environmental testing), Diagnostics & Genomics (pathology reagents, next-generation sequencing, FISH probes for cancer diagnostics), and Agilent CrossLab (instrument services, calibration, laboratory informatics, and consumables replacement).
Business Model & Competitive Advantage
Agilent's analytical instrumentation model creates recurring revenue through the instrument-consumables-services flywheel: when a pharmaceutical company installs a $200,000 Agilent liquid chromatography-mass spectrometry (LC-MS) system for small molecule drug development, it creates 10-15 years of consumable purchases (LC columns, mobile phase chemicals, calibration standards at $20,000-50,000 annually per instrument) and service contract renewals ($25,000-40,000 annually per instrument) — generating 3-5x the original instrument purchase price in recurring revenue over the system's service life. The pharmaceutical industry's drug discovery and quality control workflows are calibrated to Agilent's specific instrument parameters, method validation libraries, and software platforms (OpenLab CDS), creating switching costs that make ripping out an installed Agilent LC-MS system in a GMP-regulated pharmaceutical lab economically comparable to revalidating every analytical method from scratch.
Competitive Landscape 2025–2026
In 2025, Agilent competes in analytical instruments, laboratory informatics, and life science tools against Waters Corporation (NYSE: WAT, $3.0B revenue, LC-MS systems), Thermo Fisher Scientific (NYSE: TMO, $43B revenue, broad scientific instruments), and Bio-Rad Laboratories (NYSE: BIO, $2.8B revenue, life science research and diagnostics) for pharmaceutical R&D lab capital equipment spending and consumables volume. The FY2025 recovery (+9.4% Q4 growth) reflects the end of the pharma/biopharma destocking cycle — a correction that impacted all life science tools companies in 2023-2024 as customers depleted COVID-era inventory surpluses. The Diagnostics & Genomics segment's next-generation sequencing reagents and FISH probes serve the oncology diagnostic market, where companion diagnostic agreements with pharmaceutical companies (tying Agilent's genomic tests to specific cancer drug approvals) create regulatory moats. The 2025 strategy focuses on capital equipment upgrade cycle capture as pharma/biopharma labs replace aging instruments, expanding the Agilent CrossLab services annuity on the global installed base, and growing the cell biology and flow cytometry portfolio for next-generation drug development workflows.
The Agilent Technologies Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Agilent Technologies's journey
Leadership Team
Meet the leaders behind Agilent Technologies
Padraig McDonnell
Padraig McDonnell became Agilent's president and CEO in May 2024, becoming the fourth CEO in Agilent's history. He has been in the analytical and scientific instrument industry for over 25 years, starting his career at Hewlett-Packard in 1998. Prior to becoming CEO, he served as president of Agilent CrossLab Group since May 2020 and was named chief commercial officer in November 2021. He previously led Agilent's Chemistries and Supplies Division from 2017.
Angelica Riemann
Angelica Riemann became president of the Agilent CrossLab Group following Padraig McDonnell's promotion to CEO in 2024. She previously served as vice president and general manager of ACG's CrossLab Services Division, bringing deep expertise in laboratory services and customer support.
Jonah Kirkwood
Jonah Kirkwood was appointed chief commercial officer in 2024 to lead the One Agilent Commercial Organization. He previously served as vice president of Global Sales and brings extensive experience in commercial strategy and global sales operations.
August Specht, Ph.D.
Dr. August Specht was named Chief Technology Officer, bringing extensive R&D leadership experience from his previous role as vice president of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific.
Rodney Gonsalves
Rodney Gonsalves serves as interim CFO following Bob McMahon's departure effective July 31, 2025. He provides financial leadership during the transition period as Agilent executes its growth strategy.
Key Differentiators
Market Leader
Agilent Technologies is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $6.95B in revenue, Agilent Technologies operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Agilent Technologies with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Agilent Technologies? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Agilent Technologies Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Agilent Technologies vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →